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Statement of findings
Our aim was to identify specifically expressed genes using RNA arbitrarily primed (RAP)-
polymerase chain reaction (PCR) for differential display in patients with rheumatoid arthritis
(RA). In RA, amplification of a distinct PCR product suitable for sequencing could be
observed. Sequence analysis identified the PCR product as highly homologous to a 434 base
pair segment of the human centromere kinesin-like protein CENP-E. Differential expression
of CENP-E was confirmed by quantitative reverse transcription PCR, immunohisto-
chemistry and in situ hybridization. CENP-E expression was independent from prednisolone
and could not be completely inhibited by serum starvation. RAP-PCR is a suitable method to
identify differentially expressed genes in rheumatoid synovial fibroblasts. Also, because
motifs of CENP-E show homologies to jun and fos oncogene products and are involved in
virus assembly, CENP-E may be involved in the pathophysiology of RA.
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Introduction: Articular destruction by invading synovial
fibroblasts is a typical feature in rheumatoid arthritis (RA). Recent
data support the hypothesis that key players in this scenario are
transformed-appearing synovial fibroblasts at the site of invasion
into articular cartilage and bone. They maintain their aggressive
phenotype toward cartilage, even when first cultured and
thereafter coimplanted together with normal human cartilage into
severe combined immunodeficient mice for an extended period
of time. However, little is known about the upregulation of genes
that leads to this aggressive fibroblast phenotype. To inhibit this
progressive growth without interfering with pathways of
physiological matrix remodelling, identification of pathways that
operate specifically in RA synovial fibroblasts is required. In order
to achieve this goal, identification of genes showing upregulation
restricted to RA synovial fibroblasts is essential.
Aims: To identify specifically expressed genes using RNA
arbitrarily primed (RAP)-polymerase chain reaction (PCR) for
differential display in patients with RA.
Methods: RNA was extracted from cultured synovial fibroblasts
from 10 patients with RA, four patients with osteoarthritis (OA),
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Introduction
Inflammation, altered cellular and humoral immune
response, and synovial hyperplasia are typical findings in
rheumatoid synovium pathophysiology [1]. On the other
hand, there is increasing evidence that T-cell indepen-
dent pathways, such as upregulation of proto-oncogenes,
and one patient with psoriatic arthritis. RAP-PCR was
performed using different arbitrary primers for first-strand and
second-strand synthesis. First-strand and second-strand
synthesis were performed using arbitrary primers: US6
(5¢-GTGGTGACAG-3¢) for first strand, and Nuclear 1+
(5¢-ACGAAGAAGAG-3¢), OPN28 (5¢-GCACCAGGGG-3¢),
Kinase A2+ (5¢-GGTGCCTTTGG-3¢) and OPN24
(5¢-AGGGGCACCA-3¢) for second-strand synthesis. PCR
reactions were loaded onto 8 mol/l urea/6% polyacrylamide-
sequencing gels and electrophoresed. Gel slices carrying the
target fragment were then excised with a razor blade, eluated
and reamplified. After verifying their correct size and purity on
4% agarose gels, the reamplified products derived from the
single-strand confirmation polymorphism gel were cloned, and
five clones per transcript were sequenced. Thereafter, a
GenBank® analysis was performed. Quantitative reverse
transcription PCR of the segments was performed using the
PCR MIMIC® technique. In-situ expression of centromere
kinesin-like protein-E (CENP-E) messenger (m)RNA in RA
synovium was assessed using digoxigenin-labelled riboprobes,
and CENP-E protein expression in fibroblasts and synovium
was performed by immunogold–silver immunohistochemistry
and cytochemistry. Functional analysis of CENP-E was done
using different approaches (eg glucocorticoid stimulation,
serum starvation and growth rate analysis of synovial fibroblasts
that expressed CENP-E).
Results: In RA, amplification of a distinct PCR product
suitable for sequencing could be observed. The indicated
complementary DNA fragment of 434 base pairs from RA
mRNA corresponded to nucleotides 6615–7048 in the human
centromere kinesin-like protein CENP-E mRNA (GenBank®
accession No. emb/Z15005). The isolated sequence shared
greater than 99% nucleic acid (P = 2.9e–169) identity with the
human centromere kinesin-like protein CENP-E. Two base
changes at positions 6624 (A to C) and 6739 (A to G) did not
result in alteration in the amino acid sequence, and therefore
100% amino acid identity could be confirmed. The
amplification of 10 clones of the cloned RAP product revealed
the presence of CENP-E mRNA in every fibroblast culture
examined, showing from 50% (271.000 ± 54.000 phosphor
imager arbitrary units) up to fivefold (961.000 ± 145.000
phosphor imager arbitrary units) upregulation when compared
with OA fibroblasts. Neither therapy with disease-modifying
antirheumatic drugs such as methotrexate, gold, resochine or
cyclosporine A, nor therapy with oral steroids influenced
CENP-E expression in the RA fibroblasts. Of the eight RA
fibroblast populations from RA patients who were receiving
disease-modifying antirheumatic drugs, five showed CENP-E
upregulation; and of the eight fibroblast populations from RA
patients receiving steroids, four showed CENP-E upregulation.
Numerous synovial cells of the patients with RA showed a
positive in situ signal for the isolated CENP-E gene segment,
confirming CENP-E mRNA production in rheumatoid synovium,
whereas in OA synovial tissue CENP-E mRNA could not be
detected. In addition, CENP-E expression was independent
from medication. This was further confirmed by analysis of the
effect of prednisolone on CENP-E expression, which revealed
no alteration in CENP-E mRNA after exposure to different
(physiological) concentrations of prednisolone. Serum
starvation also could not suppress CENP-E mRNA completely.
Discussion: Since its introduction in 1992, numerous variants
of the differential display method and continuous
improvements including RAP-PCR have proved to have both
efficiency and reliability in examination of differentially
regulated genes. The results of the present study reveal that
RAP-PCR is a suitable method to identify differentially
expressed genes in rheumatoid synovial fibroblasts.
The mRNA, which has been found to be upregulated in
rheumatoid synovial fibroblasts, codes for a kinesin-like motor
protein named CENP-E, which was first characterized in 1991.
It is a member of a family of centromere-associated proteins, of
which six (CENP-A to CENP-F) are currently known. CENP-E
itself is a kinetochore motor, which accumulates transiently at
kinetochores in the G2 phase of the cell cycle before mitosis
takes place, appears to modulate chromosome movement and
spindle elongation, and is degraded at the end of mitosis. The
presence or upregulation of CENP-E has never been
associated with RA.
The three-dimensional structure of CENP-E includes a coiled-coil
domain. This has important functions and shows links to known
pathways in RA pathophysiology. Coiled-coil domains can also
be found in jun and fos oncogene products, which are frequently
upregulated in RA synovial fibroblasts. They are also involved in
DNA binding and transactivation processes resembling the
situation in AP-1 (Jun/Fos)-dependent DNA-binding in
rheumatoid synovium. Most interestingly, these coiled-coil motifs
are crucial for the assembly of viral proteins, and the upregulation
of CENP-E might reflect the influence of infectious agents in RA
synovium. We also performed experiments showing that serum
starvation decreased, but did not completely inhibit CENP-E
mRNA expression. This shows that CENP-E is related to, but
does not completely depend on proliferation of these cells. In
addition, we determined the growth rate of CENP-E high and low
expressors, showing that it was independent from the amount of
CENP-E expression. supporting the statement that upregulation
of CENP-E reflects an activated RA fibroblast phenotype.
In summary, the results of the present study support the
hypothesis that CENP-E, presumably independently from
medication, may not only be upregulated, but may also be
involved in RA pathophysiology.73
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Table 1
Clinical data of patients
Patient  Age Male/female ESR (mm/1st hour) WBC (leucocytes/nl) Medication
RA02 58 F 15 16 M, O
RA03 59 F 85 16.5 C, O
RA04 37 M 26 8.8 G, O
RA06 55 M 37 7.8 M, O
RA08 66 F 45 8.7 –
RA09 55 F 29 14.5 –
RA10 46 F 25 11.7 G, O
RA17 68 M 13 6.7 O
RA21 31 M 26 9.7 G
RA22 70 F 20 12.5 G, O
OA02 76 F 9 10.4 –
OA03 74 F 20 8.1 –
OA05 65 M 13 7.1 –
OA06 74 M 14 5.5 –
Abbreviations of disease-modifying antirheumatic drugs: C, cyclosporin A; G, gold; M, methotrexate; O, oral steroids; R, resochine; S, sulphasalazine.
production of growth factors and the release of matrix-
degrading enzymes, lead to progressive destruction of the
affected joints [2]. Recent data [3] support the hypothesis
that key players in this scenario are transformed-appearing
synovial fibroblasts at the site of invasion into articular
cartilage and bone. They maintain their aggressive pheno-
type toward cartilage even when first cultured and there-
after coimplanted together with normal human cartilage
into severe combined immunodeficiency mice for an
extended period.
To inhibit this progressive growth without interfering with
pathways of physiological matrix remodelling, identifica-
tion of pathways that operate specifically in rheumatoid
arthritis (RA) synovial fibroblasts, and not in synovial
fibroblasts of other origin [eg those of osteoarthritis (OA)],
is required. To achieve this goal, identification of genes
that show upregulation that is restricted to RA synovial
fibroblasts is essential. Various strategies have been devel-
oped to examine tissue-specific gene differences in gene
expression. Among these, the differential display approach
of RNA arbitrarily primed (RAP)-polymerase chain reac-
tion (PCR) [4] has been proved to be both efficient and
reliable in numerous experimental settings [5].
In this study, we analyzed the differential expression of
RNAs of RA fibroblasts versus OA fibroblasts derived from
synovium of patients undergoing reconstructive surgery or
synovectomy.
Materials and methods
Synovial tissue and cell culture
Synovial fibroblasts and tissue were obtained from synovial
biopsies of a total of 14 patients (Table 1). Ten patients
who met the criteria of the American College of Rheuma-
tology for RA [6] were undergoing joint surgery (synovec-
tomy or joint replacement by prosthesis implantation), and
four patients with long-term OA were undergoing joint
surgery (prosthesis implantation) because of severe articu-
lar dysfunction. In two patients with RA, fibroblast cul-
tures were obtained not only from the proliferating
synovium, but also separately from synovium that was
extracted from visible, deep intraosseus invasion areas.
Culture of synovial fibroblasts was performed as
described recently [3]. In brief, after enzymatic digestion,
fibroblasts were grown in culture flasks in Dulbeccos
Modified Eagles Medium-Cellgro (Mediatech, Washing-
ton, DC, USA) containing 10% fetal calf serum (Gibco
Life Technologies, Grand Island, NY, USA) and cultured
for four passages. To exclude contamination, synovial
fibroblasts were stained for fibroblast markers by
immunocytochemistry [>95% could be stained positively
for the fibroblast enzyme prolyl-4-hydroxylase, and none
were positive for the macrophage marker CD68 or the
neutrophil marker cathepsin G (data not shown)] and
tested for mycoplasmas. At 70–80% confluency, cells
were harvested and DNA was extracted as outlined
below and stored at –70°C. Synovial tissue used forimmunohistochemical analysis was immediately snap
frozen and stored at –70°C.
RNA extraction
Total cellular RNA was extracted using the RNeasy spin
column purification kit (Qiagen, Hilden, Germany). To
remove contaminating genomic DNA, the total RNA was
treated with DNase I (0.2U/ml; Boehringer Mannheim,
Hannheim, Germany). RNA concentrations were mea-
sured spectrophotometrically at 260nm and adjusted, and
equal aliquots were then electrophoresed on 1% agarose
gels stained with ethidium bromide to compare large and
small ribosomal RNAs qualitatively and to exclude degra-
dation. When starting with fresh RNAs, we performed one
RAP-PCR, leaving out the reverse transcriptase as a
control for DNA contamination.
RNA arbitrarily primed polymerase chain reaction of total
cellular RNA
RAP-PCR of total cellular RNA was performed as previ-
ously described [4]. In brief, three different concentrations
of RNA (500, 250 and 100ng) were used as templates for
each experiment. First-strand synthesis was carried out
using 2mmol/l first-strand arbitrary primer (for sequence see
below), and second-strand synthesis was performed using
4mmol/l arbitrary second primer and subsequently cycled
through 35 low-stringency cycles. Arbitrary primers used
were US6 (5¢-GTGGTGACAG-3¢) for first-strand synthesis,
and Nuclear 1+(5¢-ACGAAGAAGAG-3¢), OPN28 (5¢-
GCACCAGGGG-3¢), Kinase A2+ (5¢-GGTGCCTTTGG-
3¢) and OPN24 (5¢-AGGGGCACCA-3¢) for second-strand
synthesis. PCR products were loaded onto 8 mol/l urea/6%
polyacrylamide sequencing gels. Electrophoresis was per-
formed for 4–6h at 50W in 1×Tris-borate EDTA buffer.
Gels were then transferred to 3MM Whatman paper, dried
under vacuum at 80°C, and directly exposed to Kodak
BioMax™ autoradiography film (Kodak, Stuttgart,
Germany) at room temperature for 12–72h, depending on
the intensity of radiation of the amplified fragments. Several
luminescence labels (autoradiogram markers; Stratagene,
San Diego, CA, USA) were attached to the gel to facilitate
alignment of the autoradiograms with the gels for subse-
quent isolation of differentially displayed gene fragments.
Isolation and purification of differentially amplified
polymerase chain reaction products
Gel slices carrying the target fragment were then excized
with a razor blade and placed in 50ml TE buffer
(10mmol/l Tris-HCl, 1mmol/l EDTA, pH8.0). DNA was
eluted by incubating at 65°C for 3h. Eluates were taken
for reamplification of the gene fragment using the
primers of the original fingerprint and the conditions out-
lined above for 20 cycles. PCR products were routinely
checked by denaturing polyacrylamide gel electrophore-
sis, loading the reamplified product next to the original
fingerprint to verify its size and purity. To exclude conta-
mination of nondifferentially regulated gene products of
similar size to that of the regulated transcripts, thereafter
we used native polyacrylamide gels to separate the
sequences of the reamplified mixture based on single-
strand confirmation polymorphism (SSCP) as described
previously [7]. After second identification of the gene
segment using this procedure, it was cut from the SSCP
gel and reamplified a second time.
Cloning, Southern blot and sequencing
After verifying its correct size and purity on 4% agarose gels,
the reamplified products derived from the SSCP gel were
cloned into PCR®-II Topo using the TOPO-TA-Cloning®
Kit DUALPromoter (Invitrogen, De Schelp, The Nether-
lands). After blue–white screening of the clones, 10 white
colonies and one blue colony were picked and suspended in
50ml water. Aliquots of these bacterial suspensions were
checked by high-stringency PCR for the presence and the
correct length of inserts using the T7 and the M13 (or M20)
reverse sequencing primers. Clones of the correct length
were subsequently grown overnight in 5ml LB medium
containing 50mg/ml of ampicillin for plasmid isolation. Five
clones per transcript were sequenced with the Applied
Biosystems 373 automatic sequencer using the Perkin
Elmer (Norwalk, CT, USA) DNA sequencing kit. The data-
bases of the National Center for Biological Information were
screened to align the obtained sequences with known com-
plementary DNA clones, genomic clones and cloned
expressed sequence tags.
If sequences were multiply represented and confirmed
within the majority of the clones resulting from one RAP-
PCR product, inserts were reamplified and used as probes
against Southern blots of the original fingerprint gel. This
procedure confirms that selected sequences were in fact
differentially amplified in the original fingerprint gels. For
this, DNA from RAP-PCR fingerprint gels was transferred
to nylon membranes (Duralon-UV, Stratagene, San Diego,
CA, USA) by capillary action in a 10×saline sodium citrate
(SSC) buffer overnight. After ultraviolet cross-linking,
blots were prehybridized and hybridized using established
protocols [8].
Confirmation of differential expression by quantitative
reverse transcription polymerase chain reaction
Quantitative reverse transcription PCR was performed
using the PCR MIMIC® technique (Clontech, Palo Alto,
CA, USA). In this competitive PCR method, one set of
primers is used to amplify both the target complementary
DNA and the nonhomologous internal standard. As the
amplified PCR fragments are designed to be different in
length, they can be distinguished by gel electrophoresis.
Using this method, relative transcript abundances of the
different fibroblast populations could be compared after
standardization of the coamplified highly abundant internal
standard DNA. Radioactive PCR products amplified using
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primers were evaluated by phosphor imaging densitometry
(Phosphor Imager; Molecular Dynamics, Sunnyvale, CA,
USA) and subsequent data analysis was performed using
the Ambis software (Imagequant; Molecular Dynamics).
Each PCR amplification was performed in quadruplicate,
and relative amount was calculated as phosphor imager arbi-
trary units (PAU) of CENP-E amplicons of the RA and the
OA fibroblast cultures.
Mean ± standard error of the mean was calculated for each
of the individual RA fibroblast cultures and compared
with the CENP-E production of all OA synovial fibroblast
cultures. Statistical analysis was performed using the
Mann–Whitney test for nonpaired parameters. P<0.05
was regarded as statistically significant.
In-situ expression of CENP-E messenger RNA in
rheumatoid arthritis synovium
Plasmids containing the isolated CENP-E gene segment
were extracted and purified using Nucleobond-AX-
Columns (Macherey-Nagel, Düren, Germany) and lin-
earized to permit generation of antisense and sense
riboprobes. In-situ hybridization was performed as pub-
lished recently [3,9]. In brief, antisense and sense RNA
probes were transcribed by T3 and T7 RNA polymerase
(Stratagene). Probes were labelled with digoxigenin–
uridine triphosphate (Boehringer Mannheim). Frozen sec-
tions (4–6mm thick) were cut and fixed in 3% buffered
paraformaldehyde for 1h at room temperature( 20–22°C).
The sections were rinsed in 2×SSC/0.25% acetic anhy-
dride (Fisher Scientific, Springfield, NJ, USA) for 15min at
room temperature. After a rinsing step with 0.1mol/l tri-
ethanolamine–HCl (pH8.0), prehybridization was per-
formed. After the prehybridization, digoxigenin-labelled
antisense or sense probe (for control) was applied to the
tissue specimens in 15l prehybridization buffer. The slides
were sealed with nail polish and hybridized for 12h in a
humid chamber at 50°C. Then slides were washed at room
temperature with SSC and sodium chloride-Tris-EDTA
(STE) buffer. After digestion for 1h at 37°C with 20g/ml
RNAse A (Boehringer Mannheim), slides were rinsed with
2×SSC, 50% formamide for 5min, followed by 1×SSC,
0.1% sodium dodecyl sulphate for 10min, and 0.5×SSC,
0.1% sodium dodecyl sulphate for 15min at 50°C. The
slides were washed and developed using antidigoxigenin-5
nm gold-labelled antibody complex (Goldmark Biologicals,
Phillipsburg, NJ, USA) according to a modification to the
protocol of Komminoth et al [9].
Immunogold–silver immunohistochemistry for CENP-E
RA and OA synovial fibroblasts cultured in chamber wells
and snap frozen sections (4–6mm thick) were fixed for 5min
in acetone and covered with a 4% milk, 2% normal horse
serum Tris buffer for 30min at room temperature
(20–22°C) to block nonspecific binding. Then, slides were
washed and incubated with monoclonal mouse anti-CENP-
E-antibody [10,11], or antifibroblast antibodies (Dianova,
Hamburg, Germany). The slides were washed and incu-
bated with a biotinylated goat antimouse antibody
(Dianova) diluted 1:600 in Tris buffer. After washing, sec-
tions were incubated with peroxidase-conjugated strepta-
vidin (Dianova), diluted 1:600 in Tris buffer. After a rinsing
step, 6nm gold-labelled goat antihorseradish peroxidase
(Dianove), diluted 1:40 in Tris buffer was applied. Signal
detection by the immunogold–silver technique was per-
formed as described above.
Immunohistochemical double labelling (alkaline
phosphatase anti-alkaline phosphatase method)
Double labelling was performed using the alkaline phos-
phatase anti-alkaline phosphatase method with mono-
clonal antibodies against human fibroblasts (Dianova).
Sections were covered with a 4% milk, 2% normal horse
serum buffer for 30min at room temperature to block
nonspecific binding, washed in Tris-NaCl (pH7.5) and
incubated for 45min at room temperature (20–22°C)
with the primary antibodies diluted 1:50 to 1:100 in
Tris–NaCl (pH7.5). Colour development was performed
as previously published [3].
Negative controls were performed in each of the tech-
niques described above by omitting the primary antibody,
incubation with isotype-matched controls or using the
sense probe in the in situ hybridization assay.
Glucocorticoid stimulation
Three of the RA fibroblast populations showing upregula-
tion of CENP-E (RA08, RA09 and RA21) and three popu-
lations showing no upregulation (RA10, RA17 and RA22)
were adjusted to 0.5×106 cells and incubated with physio-
logical concentrations of 10–7 and 10–9mmol/l prednisolone
for 6h. Thereafter, CENP-E messenger (m)RNA was mea-
sured using reverse transcription PCR as outlined above.
Serum starvation
Three of the RA fibroblast populations showing upregulation
of CENP-E (RA08, RA09 and RA21) and three populations
showing no upregulation (RA10, RA17 and RA22) were
adjusted to 0.5×106 cells and were cultured for 72h without
fetal calf serum. Thereafter, CENP-E mRNA was measured
using reverse transcription PCR as outlined above.
Growth rate
Cells (105) of RA fibroblast populations showing upregula-
tion of CENP-E (RA08, RA09 and RA21) and showing no
upregulation (RA10, RA17 and RA22) were cultured in
quintuplicate in 24 well plates. To evaluate the growth
rate, cell counts were performed on days 2, 3, 4 and 5, and
increase in cell numbers from day to day was evaluated
using a Neubauer counting chamber and measured as per-
centage per day.
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RNA arbitrarily primed polymerase chain reaction
Total RNA, prepared from synovial fibroblasts from 10
patients with RA and four patients with OA, was used for
RAP-PCR. In total, approximately 150 RNAs were ampli-
fied using RAP-PCR per primer pair, of which most were
expressed both by RA and OA synovial fibroblasts. Approx-
imately 2% of the RNAs showed a polymorphism within
the RA group. Five RAP-products were differentially
expressed between RA and nonRA synovial fibroblasts, and
one PCR product was suitable for further analysis. The
autoradiography of the original RAP-PCR gel is shown in
Figure 1, and the arrowheads indicate the complementary
DNA fragment that we isolated for further characterization.
Cloning and sequencing of differentially amplified RNA
arbitrarily primed product
The indicated complementary DNA fragment of 434 base
pairs from RA mRNA corresponded to nucleotides
6615–7048 in the human centromere kinesin-like protein
CENP-E mRNA (GenBankÒ accession No. emb/Z15005)
The RAP-PCR product was located entirely within the
open reading frame. The isolated sequence shared greater
than 99% nucleic acid (P=2.9e–169) identity with the
human centromere kinesin-like protein CENP-E. Two
base changes at positions 6624 (A to C) and 6739 (A to G)
did not result in alteration of the amino acid sequence,
and therefore 100% amino acid identity could be con-
firmed. The amplification of 10 clones of the cloned RAP
product revealed the presence of CENP-E mRNA in
every fibroblast culture examined.
We confirmed the predicted upregulation of CENP-E in
RA using quantitative reverse transcription PCR. When
analyzed by phosphor imaging densitometry, significant
upregulation of CENP-E mRNA production in RA syn-
ovial fibroblasts as compared with OA synovial fibroblasts
(173.000±46.000 PAU) was observed in eight out of 12
synovial fibroblasts populations of patients with RA.
CENP-E upregulation among the fibroblast populations
ranged from approximately 50% (271.000 PAU, culture
RA04) to fivefold (961.000PAU, culture RA21) upregula-
tion (Fig. 2a). In six additional synovial fibroblast popula-
tions, the RA fibroblasts also showed an upregulation of
CENP-E expression as compared with psoriatic arthritis
fibroblasts (Fig. 2b). Of interest, neither therapy with
disease-modifying antirheumatic drugs such as methotrex-
ate, gold, resochine or cyclosporine A, nor therapy with
oral steroids showed an influence on CENP-E expression
in the RA fibroblasts. Of the eight RA fibroblast popula-
tions from RA patients receiving disease-modifying
antirheumatic drugs, five showed an CENP-E upregula-
tion; and of the eight fibroblast populations from RA
patients receiving steroids, four showed a CENP-E upreg-
ulation. Furthermore, no difference in upregulation was
seen in the RA synovial fibroblasts obtained from the
intraosseus invasion areas (RA3K and RA9K), indicating a
general upregulation of CENP-E in all synovial tissue
compartments.
Confirmation of CENP-E protein synthesis
Synthesis of CENP-E was not only confirmed on the
mRNA level as outlined above, but also on the protein
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Figure 1
Original fingerprint [RNA arbitrarily primed (RAP)-polymerase chain
reaction (PCR)] of RNA of synovial fibroblasts derived from 10
different patients with rheumatoid arthritis and six patients with
osteoarthritis. Each RAP-PCR was performed in triplicate using three
different RNA concentrations. Left two lanes: DNA marker. Triplicate
lanes 1–10 show the RAP-PCR of the synovial fibroblasts of the 10
rheumatoid arthritis patients, and lanes 11–16 show the RAP-PCR of
those of the osteoarthritis patients. The arrow indicates the
differentially displayed gene fragment seen in the rheumatoid arthritis
patients (434 base pairs), which was used for subsequent analysis.level by immunohistochemistry using monoclonal anti-
bodies against human CENP-E. As illustrated in Figure 3,
cultured rheumatoid synovial fibroblasts expressed inten-
sive amounts of CENP-E (Fig. 3a), whereas in OA fibrob-
lasts CENP-E production was below detection level
(Fig. 3b). Figure 3c shows the positive control using antifi-
broblast antibodies.
Expression of CENP-E in rheumatoid synovium
Numerous synovial cells of the patients with RA showed a
positive  in situ signal for the isolated CENP-E gene
segment, confirming CENP-E mRNA production in
rheumatoid synovium, whereas in OA synovial tissue
CENP-E mRNA could not be detected. CENP-E
expressing cells were found throughout the synovium,
both in the lining layer as well as in the sublining. Because
numerous CENP-E expressing cells showed an atypical
fibroblast phenotype, we performed double-labelling
using monoclonal fibroblast antibodies. The majority of
CENP-E protein-expressing cells could be double-
labelled with fibroblast antibodies, indicating that the
CENP-E production seen in the cultured cells is not an
effect caused by culture conditions. Figures 4a and 4b
show synovial fibroblasts intensively expressing mRNA
for the CENP-E gene segment isolated by RAP-PCR.
To evaluate whether CENP-E mRNA production led to
protein production detectable by immunohistochem-
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Figure 2
Quantitative reverse transcription polymerase chain reaction of the
CENP-E gene segment followed by phosphor imaging densitometry
evaluation. The polymerase chain reaction MIMIC® technique was
used. (a) Significant upregulation in CENP-E in eight out of 12
rheumatoid arthritis synovial fibroblast cultures (white bars) as
compared with all osteoarthritis fibroblast cultures (dotted bar; total
n= 4); whereas four rheumatoid arthritis fibroblast populations did not
show an upregulation in CENP-E upregulation (black bars). Values are
shown as phosphor imager arbitrary units (PAU, mean ± standard
error of the mean). Each MIMIC® was performed in quadruplicate.
P<0.05 was considered statistically significant. (b) Significant
upregulation in six additional rheumatoid arthritis synovial fibroblast
cultures (white bars) as compared with psoriatic arthritis fibroblasts
(generous gift from E Märker-Herrmann, University of Mainz,
Germany). Ratio of intensities are shown (when compared to
standard 18S RNA).
(a) (b)
Figure 3
Immunocytochemistry of cultured rheumatoid arthritis fibroblasts using
monoclonal antibodies against human CENP-E protein [10,11]. Note
the strong expression of CENP-E protein rheumatoid fibroblasts (a) in
comparison with the absence of CENP-E protein in osteoarthritis
fibroblasts (b). (c) The positive control was performed with
antifibroblast antibodies. Immunogold–silver staining, original
magnifications ×800 (a, b) and ×1000 (c).
(a) (b) (c)istry, monoclonal antibodies directed against human
CENP-E [10,11] were used. The most intensive CENP-
E protein expression was found within highly inflamed
areas in the sublining, and, to a lesser extent, in the
lining layer. Figure 4c shows a synovial section with
numerous synovial fibroblasts intensively expressing
CENP-E protein.
Functional assays
As outlined above, CENP-E expression was independent
from medication. This was further confirmed by analysis
of the effect of prednisolone on CENP-E expression,
which revealed no alteration in CENP-E mRNA after
exposure to different (physiological) concentrations of
prednisolone (Fig. 5). Serum starvation was also not able
to suppress CENP-E mRNA completely. As shown in
Figure 5, although in lesser amounts, CENP-E mRNA
can still be detected in all RA synovial fibroblast popula-
tions, even after numerous days of serum starvation.
Determination of the growth of CENP-E high and low
expressors showed that the growth rate was slightly
increased in the CENP-E high expressors, but by statisti-
cal criteria independent from the amount of CENP-E
expression (Table 2). Also, the doubling time of CENP-E
high and low expressors did not differ (data not shown).
Discussion
Since its introduction in 1992 [12], numerous variants of
the differential display method [13] and continuous
improvements including RAP-PCR [14] have proved to
have both efficiency and reliability in examination of dif-
ferentially regulated genes. Although the majority of
experimental approaches have addressed malignant dis-
eases [13,15,16], the results of this study reveal that, along
with differential subtraction [17] and the original differen-
tial display [18], RAP-PCR is a particularly suitable
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Figure 4
Demonstration of CENP-E messenger RNA and protein in rheumatoid synovium by in situ
hybridization and immunohistochemistry. (a, b) A digoxigenin-labelled RNA probe transcribed from
the amplified RNA arbitrarily primed-PCR gene product is used on rheumatoid arthritis snap-frozen
sections. Double-labelling for CENP-E messenger RNA (black staining), and alkaline phosphatase
antialkaline phosphatase counterstaining using anti-fibroblast antibodies (red staining) shows
CENP-E expression in numerous fibroblasts througout the synovium (a, arrows). (b) The intensive
CENP-E messenger RNA expression in two synovial fibroblasts. (c) Shows numerous fibroblasts
expressing CENP-E protein [black staining (arrows), counterstaining with fast red]. Original
magnifications ×300 (a, c) and ×600 (b).
(a) (b) (c)
Figure 5
CENP-E regulation. The figure shows CENP-E messenger RNA in
CENP-E high (right lanes 3/4, 7/8, 11/12 and 15/16) and CENP-E
low (left lanes 1/2, 5/6, 9/10 and 13/14) expressing rheumatoid
arthritis synovial fibroblast populations after different prednisolone
exposure (lanes 1–8) and serum starvation (lanes 9–12). As compared
with unstimulated fibroblasts (lanes 13–16) no significant alteration in
CENP-E messenger RNA expression, either in CENP-E high- or in
CENP-E low-expressing fibroblast populations, can be observed after
prednisolone exposure. Serum starvation was also not able to
suppress CENP-E messenger RNA completely (lanes 9–12).method to identify differentially expressed genes in
rheumatoid synovial fibroblasts.
The mRNA, which has been found to be upregulated in
rheumatoid synovial fibroblasts, codes for a kinesin-like
motor protein named CENP-E, which was first character-
ized in 1991 [10]. It is a member of a family of centromere-
associated proteins, of which six (CENP-A to CENP-F)
are currently known. The complete CENP-E gene spans a
length of 8371 bases, the open reading frame encodes
2663 amino acids, and the respective protein has a molec-
ular weight of 312kDa and is a member of the human cen-
tromere–kinetochore complex [11]. CENP-E itself is a
kinetochore motor, which accumulates transiently at kine-
tochores in the G2 phase of the cell cycle before mitosis
takes place, appears to modulate chromosome movement
and spindle elongation, and is degraded at the end of
mitosis [11,19–22]. Consistently, inhibition of the CENP-
E protein by specific antibodies causes cell cycle arrest at
metaphase [11]. In addition, further research showed that
kinesin-like proteins, including CENP-E, specifically reg-
ulate microtubule formation and the consecutive move-
ment of chromosomes during mitosis, and therefore are
crucial for cell division [23].
Interestingly, the presence or upregulation of CENP-E
has never been associated with RA, although antibodies to
the CENP family are frequently found in numerous
rheumatic diseases [24], and CENP-E has recently been
proposed to be an autoantigen in the limited form of sys-
temic sclerosis [25].
The three-dimensional structure of CENP-E includes a
coiled-coil domain. This has important functions that have
links to known pathways in RA pathophysiology. Coiled-
coil domains can also be found in jun and fos oncogene
products [26,27], which are frequently upregulated in RA
synovial fibroblasts [28]. They are also involved in DNA
binding and transactivation processes, resembling the situ-
ation in activating protein-1 (Jun/Fos)-dependent DNA-
binding in rheumatoid synovium [29]. Most interestingly,
these coiled-coil motifs are crucial for the assembly of viral
proteins [30,31], and the upregulation of CENP-E might
reflect the influence of infectious agents in RA synovium
[1,32]. In addition, CENP-E may also be involved in acti-
vation of rheumatoid synovial fibroblasts, because pres-
ence of CENP-E has been found to correlate with the
active state of centomeres in translocations [33]. These
pathways may include a distinct dysregulation of the cell
cycle (eg rare activation steps in the formation of neocen-
tromeres [34,35]), because rheumatoid synovial fibrob-
lasts, although they have a transformed appearance, do not
reveal an increased rate of proliferation in vitro or in vivo
[36,37].
We also performed experiments showing that serum starva-
tion decreased, but not completely inhibited CENP-E
mRNA expression, showing that CENP-E is related to but
does not completely depend on proliferation of these cells.
In addition, we determined the growth rate of CENP-E
high and low expressors, showing that it was independent
on the amount of CENP-E expression, supporting the
statement that upregulation of CENP-E reflects an acti-
vated RA fibroblast phenotype.
In summary, the results of this study support the hypothe-
sis that CENP-E, presumably independently from med-
ication, may not only be upregulated, but also be involved
in RA pathophysiology.
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